[go: up one dir, main page]

AR124526A1 - Composiciones farmacéuticas tópicas y métodos - Google Patents

Composiciones farmacéuticas tópicas y métodos

Info

Publication number
AR124526A1
AR124526A1 ARP210103688A ARP210103688A AR124526A1 AR 124526 A1 AR124526 A1 AR 124526A1 AR P210103688 A ARP210103688 A AR P210103688A AR P210103688 A ARP210103688 A AR P210103688A AR 124526 A1 AR124526 A1 AR 124526A1
Authority
AR
Argentina
Prior art keywords
composition
compound
topical pharmaceutical
pharmaceutically acceptable
composition according
Prior art date
Application number
ARP210103688A
Other languages
English (en)
Inventor
Kollol Pal
Abhijit Bhat
Jay Birnbaum
Vijendra Nalamothu
Srikanth Manne
Gayathri Krishnan
Jean-Philippe Therrien
Original Assignee
Pyramid Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pyramid Biosciences Inc filed Critical Pyramid Biosciences Inc
Publication of AR124526A1 publication Critical patent/AR124526A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a una composición farmacéutica tópica que contiene N-[(1S)-1-(5-fluoropirimidin-2-il)etil]-3-(5-isopropoxi-1H-pirazol-3-il)-3H-imidazo[4,5-b]piridin-5-amina (en lo sucesivo también denominada “Compuesto A”), o una sal farmacéuticamente aceptable del mismo; al uso de la composición farmacéutica tópica como medicamento; a procesos para la preparación de dicha composición farmacéutica tópica; a ciertos métodos nuevos de tratamiento de un trastorno inflamatorio de la piel, particularmente psoriasis, mediante la administración de una composición farmacéutica tópica que contiene el Compuesto A o una sal farmacéuticamente aceptable del mismo; y a nuevas formas cristalinas de una sal mesilato del Compuesto A. Reivindicación 1: Una composición farmacéutica tópica que comprende: a) Compuesto A o una sal farmacéuticamente aceptable del mismo: Compuesto A de fórmula (1); b) al menos un potenciador de la permeación; y c) uno o más excipientes farmacéuticamente aceptables. Reivindicación 5: La composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, que comprende uno o más potenciadores de la permeación seleccionados entre dietilenglicol monoetiléter, un alcohol de ácido graso, un glicol, un disolvente aprótico o cualquier combinación de los mismos. Reivindicación 10: La composición de acuerdo con cualquiera de las reivindicaciones 5 a 9, en donde el dietilenglicol monoetiléter está presente en una cantidad del 3 al 40% p/p de la composición total. Reivindicación 12: La composición de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición comprende además un antioxidante. Reivindicación 16: La composición de acuerdo con cualquiera de las reivindicaciones 12 a 15, en donde el antioxidante está presente en la composición de aproximadamente el 0,01% a aproximadamente el 1,0% p/p de la composición total. Reivindicación 17: La composición de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición comprende dietilenglicol monoetiléter, alcohol oleílico y un antioxidante soluble en aceite. Reivindicación 18: La composición de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición comprende entre 0,005% p/p y 5% p/p (convenientemente entre 0,005% p/p y 3% p/p y más convenientemente entre 0,005% p/p y 0,15% p/p) del Compuesto A o una sal farmacéuticamente aceptable del mismo.
ARP210103688A 2020-12-29 2021-12-28 Composiciones farmacéuticas tópicas y métodos AR124526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063131647P 2020-12-29 2020-12-29

Publications (1)

Publication Number Publication Date
AR124526A1 true AR124526A1 (es) 2023-04-05

Family

ID=79283242

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103688A AR124526A1 (es) 2020-12-29 2021-12-28 Composiciones farmacéuticas tópicas y métodos

Country Status (8)

Country Link
US (1) US20240092778A1 (es)
CN (1) CN116782883A (es)
AR (1) AR124526A1 (es)
AU (1) AU2021415273A1 (es)
CA (1) CA3204701A1 (es)
IL (1) IL303818A (es)
TW (1) TW202239410A (es)
WO (1) WO2022144758A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250129813A (ko) * 2023-01-13 2025-08-29 선전 뉴델 바이오텍 씨오., 엘티디. 화합물 1의 아토피성 피부염의 치료 또는 예방에서의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
CA3204701A1 (en) 2022-07-07
CN116782883A (zh) 2023-09-19
WO2022144758A1 (en) 2022-07-07
AU2021415273A9 (en) 2024-10-03
AU2021415273A1 (en) 2023-06-29
US20240092778A1 (en) 2024-03-21
IL303818A (en) 2023-08-01
TW202239410A (zh) 2022-10-16

Similar Documents

Publication Publication Date Title
ECSP21073246A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
NI202000078A (es) Compuestos heteroaril tetracíclicos
AR134152A2 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
AR115283A1 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílicoe
DOP2025000250A (es) Compuestos de pirido[4,3-d]pirimidina
RU2012140955A (ru) Фармацевтические композиции спиро- оксиндолового соединения для местного введения и их применение в качестве терапевтических агентов
EA018545B1 (ru) Терапевтические композиции
ECSP21039539A (es) Mezclas y composiciones que comprenden 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona, y métodos de uso de los mismos
CL2024000714A1 (es) Compuestos espirocíclicos
AR096346A1 (es) Composiciones antiparasitarias de espiro-isoxazolina de acción prolongada
MX2023009282A (es) Compuesto profarmaco, metodo de preparacion del mismo y uso del mismo.
AR124526A1 (es) Composiciones farmacéuticas tópicas y métodos
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
UY40282A (es) Compuestos amido-heteroaromáticos
BR112022011284A2 (pt) Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
MX2024010104A (es) Compuesto bicíclico condensado que contiene pirrolinona.
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
ES2648190T3 (es) Compuestos para su uso en el tratamiento de la filariasis
CL2025001760A1 (es) Compuesto quimérico protac, método de preparación del mismo y uso del mismo
AR057067A1 (es) Procedimiento para preparar sales de tiotropio, sales de tiotropio como tales y composiciones farmaceuticas de las mismas
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
WO2020113050A8 (en) Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
AR068346A1 (es) Metodos para lograr bienestar sexual aumentado usando composiciones anhidras
FI4041186T3 (fi) Vedetön lääkekoostumus psoriaasin ylläpitohoitoon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal